Blue Water Ventures International, Inc. · OTC:BWVI
Blue Water Ventures International — Psycheceutical Bioscience — Investor Presentation (August 2023)
29 slides from Blue Water Ventures International's investor presentation, August 2023
Slide 1: Investor Presentation
STATE-OF-THE-ART PSYCHEDELIC DELIVERY TECHNOLOGIES INVESTOR PRESENTATION AUGUST 2023
Slide 2: Our Vision
OUR VISION Using patented, cutting-edge delivery technologies to provide safe, effective, and non-hallucinogenic psychedelic pharmaceutical medicines. Investor Presentation | Aug. 2023 | 2
Slide 3: Disclaimer
DISCLAIMER This presentation of Psycheceutical Bioscience, Inc., together with its wholly owned subsidiary Psycheceutical, Inc. (the “Company” or global economy; the Company’s ability to implement its strategy or operate its business as the Company currently expects; the “Psycheceutical”), is for in
Slide 4: Background
BACKGROUND Psycheceutical, Inc. is a bioscience company that is Our next-generation patented drug delivery fundamentally changing the delivery of psychedelics for technologies, via systemic and non-systemic routes of the treatment of mental health disorders, representing an administration, are expec
Slide 5: Executive Summary
EXECUTIVE SUMMARY • We’ve assembled an incredibly talented and diverse • Drug development is ongoing, and Psycheceutical has team, consisting of medical doctors, neurosurgeon, initiated Phase I clinical studies with the first candidate neuroscientist, biotechnology scientists, FDA in July 2023 and i
Slide 6: Market Need for New Mental Health Treatments
MARKET NEED FOR NEW MENTAL HEALTH TREATMENTS During the next few years, a higher frequency of mental health disorders combined with greater mental health awareness is expected to fuel a global market expansion for psychedelic medicines. Mental health disorders result in enormous economic costs to th
Slide 7: The Problem
THE PROBLEM Suboptimal Dosing Prevents the Widespread Use of Lifesaving Psychedelics • Currently available dosage forms and routes of • Psychedelic drugs often require administration in administration are not optimized for enhancing clinical settings, which increases the cost of care efficacy and re
Slide 8: The Solution: Psycheceutical Technologies
THE SOLUTION: PSYCHECEUTICAL TECHNOLOGIES State-Of-The-Art Delivery Technologies for Safe Psychedelic Dosing Psycheceutical is removing the barriers of Our technology is also designed to be administered at- psychedelic medicines by employing two next- home or on-the-go, which could greatly lower the
Slide 9: Psycheceutical's Non-Systemic Delivery Solution
PSYCHECEUTICAL’S NON-SYSTEMIC DELIVERY SOLUTION Our patented NeuroDirect™ non-systemic delivery technology is being designed to deliver neuro- affective compounds directly to the nervous system via topical application at the back of the neck. This delivery system is intended to allow rapid therapeut
Slide 10: NeuroDirect Delivery Goals
NEURODIRECT DELIVERY GOALS NeuroDirect Patented Delivery Technology Goals • Direct delivery of neuro-affective agents into the • Minimize significant adverse reactions (NeuroDirect nervous system, designed for efficacy at much lower delivery reduces symptoms without significant adverse doses reactio
Slide 11: Psycheceutical's Systemic Delivery System
PSYCHECEUTICAL’S SYSTEMIC DELIVERY SYSTEM Our patented Janus particles systemic delivery system, based on recent breakthrough discoveries at the University of Michigan, is being developed to cross the blood-brain barrier to target specific cells and deliver multiple medicines at different times and
Slide 12: Patented Janus Particles Manufacturing
PATENTED JANUS PARTICLES MANUFACTURING We believe that our patented manufacturing process will be able to deliver psychedelics and other complementary compounds at scale, in nearly any required size or shape, in a cost-effective and consistent manner. The vision is that our Janus particles will be a
Slide 13: Janus Particles Goals
JANUS PARTICLES GOALS Janus Particle Patented Manufacturing Technology Goals • Issued and pending patents provide worldwide • Process to allow for the efficient production of a high exclusivity for manufacturing and sale of products. variety of particles with the easy ability to tune for size, shape
Slide 14: Compounds & Delivery Methods in Our Focus
COMPOUNDS & DELIVERY METHODS IN OUR FOCUS Molecules We Are Targeting Potential Delivery Methods KETAMINE PSILOCYBIN IBOGAINE ORAL TOPICAL NASAL MDMA DMT LSD TRANSDERMAL RECTAL Investor Presentation | Aug. 2023 | 14
Slide 15: Who We Are
WHO WE ARE FDA Drug Development Veterans We’ve assembled an incredibly talented and diverse team, consisting of consisting of medical doctors and specialists, biotechnology scientists, FDA regulatory advisors, and business development experts. Technology and Mental Health Science Experts Our visiona
Slide 16: Leadership
LEADERSHIP CHAD HARMAN DR. ANISH TUTEJA MICHAEL HLAVSA KEVIN HARRINGTON Chief Executive Officer Chief Science Officer Chief Financial Officer Strategic Advisor Chad Harman is a 25-year cannabis Dr. Anish Tuteja is Professor Michael Hlavsa has 44 years of Kevin Harrington is a famed and health insura
Slide 17: Medical Advisory Board
MEDICAL ADVISORY BOARD JULIAN E. BAILES, MD DR. THOMAS CABELL DR. TONY STRICKLAND Chief Medical Officer, Board Member Medical Advisor Medical Advisor Julian E. Bailes, MD is a recognized leader Dr. Thomas Cabell is a cardiologist and Dr. Tony Strickland is a board-certified in the field of neurosurg
Slide 18: Science Team
SCIENCE TEAM RONALD DR. ARIC DR. ANISH DR. JAMES AUNG-DIN, MD LOGSDON DHANARA JAN CAPPOLA Clinical Advisor Scientific Director R&D Advisor Clinical Advisor Dr. Ronald Aung-Din practices Dr. Aric Logsdon is a biomedical Dr. Anish Dhanarajan has a Ph.D. in Dr. James J. Cappola has over 25 General Neur
Slide 19: Psycheceutical's Brand Awareness
PSYCHECEUTICAL’S BRAND AWARENESS Featured Articles In: Featured Speakers At: “Shark Tank’s Kevin Harrington “Psycheceutical Licenses Invests in Psychedelics New Delivery Technologies Company Psycheceutical” For Psychedelic Medicines” Wonderland:Miami “Biotech Company Earns Two “Novel Psychedelic Tre
Slide 20: Our Strategy
OUR STRATEGY Our goal is to develop our assets for all targeted areas of commercial use, focusing initially on near-term licensing and strategic partnership opportunities, while exploring on an ongoing basis all avenues for achieving maximum benefit from our assets for the pharmaceutical and drug de
Slide 21: Business Model: Capturing Dual Revenue Streams
BUSINESS MODEL: CAPTURING DUAL REVENUE STREAMS Psycheceutical intends to leverage its novel technology in two highly profitable sectors: licensing technology & drug development. B2B Channel In-House IP and Drug Development It is our intention to license our drug delivery technology We intend to deve
Slide 22: Drug Pipeline
DRUG PIPELINE Investor Presentation | Aug. 2023 | 22
Slide 23: PSY-007 for PTSD
PSY-007 FOR PTSD NeuroDirect Ketamine Topical for the Treatment of PTSD • Multiple layers of patent protection • Observational data reflects reduction in symptoms via Hamilton depression scale (FDA gold standard) in • Method of use: Our patent restricts anyone from 80% of patients without typical si
Slide 24: PSY-034 for Addiction
PSY-034 FOR ADDICTION NeuroDirect Topical for the Treatment of Addiction • Multiple layers of patent protection • Provisional patent in-process • Method of use: Our patent restricts anyone from • In-house synthesis of API, formulation development, and marketing or selling a topical product as an cli
Slide 25: PSY-311, PSY-322 & PSY-345 for Traumatic Brain Injury (TBI)
PSY-311, PSY-322 & PSY-345 FOR TRAUMATIC BRAIN INJURY (TBI) TBI-Related Neuropsychiatric and Neurocognitive Disorders Compounds targeting novel mechanisms of TBI pathophysiology • PSY-311 – Finalizing license agreement with • Yearly market opportunity $17B+ prominent university Lead Candidate patent
Slide 26: Strategic Partnership: Vici Health Sciences
STRATEGIC PARTNERSHIP: VICI HEALTH SCIENCES Psycheceutical has entered into a Binding Option Agreement to acquire a controlling interest in Vici Health Sciences to assist in developing our our future IP and in-house formulations. Vici Health Sciences are U.S.-based experts in formulation and analyti
Slide 27: Current & Upcoming Value-Driving Milestones
CURRENT & UPCOMING VALUE-DRIVING MILESTONES • REG CF $5MM capital raise • Started PSY-007 NeuroDirect ketamine Phase I Q3 clinical trial • Finalize Vici acquisition • File PSY-034 formulation patent 2023 • Complete Phase I trial for PSY-007 NeuroDirect ketamine Q4 • License new NCE for neurological
Slide 28: Why Invest in Psycheceutical Now
WHY INVEST IN PSYCHECEUTICAL NOW • Peer-Reviewed Observational Clinical Data Data validates PSY-007 NeuroDirect ketamine topical for PTSD as fast-acting and 80% effective at treating symptoms, with no adverse events or psychogenic effects felt by patients. • First-Ever Clinical Trials for Ketamine T
Slide 29: Thank You!
THANK YOU! psycheceutical.com | info@psycheceutical.com
Psycheceutical Bioscience — Investor Presentation (August 2023) on 6ix